Aridis Pharmaceuticals IncAridis Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This SDG score for Aridis Pharmaceuticals Inc indicates the company's transparency towards the UN Sustainable Development Goals. Detailed ESG analysis of Aridis Pharmaceuticals Inc can be accessed by signing up for free. This article includes a questions and answers table about Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 6.0, social score of 5.3 and governance score of 6.9.

SDG Transparency Score for Aridis Pharmaceuticals Inc 
Low
0 - 3

6.1

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Aridis Pharmaceuticals Inc 
6.0

Environmental

5.3

Social

6.9

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
586Traphaco JSC
6.2
High
586Xenon Pharmaceuticals Inc
6.2
High
623Aridis Pharmaceuticals Inc
6.1
High
623Achieve Life Sciences Inc
6.1
High
623Anatara Lifesciences Ltd
6.1
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Aridis Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Aridis Pharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Aridis Pharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Aridis Pharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does Aridis Pharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Aridis Pharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Aridis Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Sorry!

Failed to process!